Beryl Drugs Promoter Sudhir Sethi Buys Shares, Raises Stake to 9.58%

OTHER
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Beryl Drugs Promoter Sudhir Sethi Buys Shares, Raises Stake to 9.58%
Overview

Beryl Drugs Limited announced that promoter Sudhir Sethi acquired 7,500 shares through market transactions on March 23, 2026. This acquisition increases his total shareholding to 4,86,483 shares, representing 9.58% of the company's total voting capital. The stake increase is a result of open market purchases.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Beryl Drugs Promoter Sudhir Sethi Acquires Stake

Promoter Sudhir Sethi acquired 7,500 equity shares of Beryl Drugs Limited on March 23, 2026, through open market purchases. This transaction boosted his total shareholding to 4,86,483 shares, now representing 9.58% of the company's total voting capital. His previous holding was 4,78,983 shares, or 9.44%, meaning this purchase adds 0.14% to his stake.

Market Signals Confidence

An increase in promoter stake is often seen by the market as a sign of confidence in the company's future prospects. Sudhir Sethi's purchase signals his increased personal investment and belief in Beryl Drugs.

About Beryl Drugs

Beryl Drugs Limited, founded in 1993 and based in Indore, manufactures and markets pharmaceutical products, including bulk drugs and formulations. Sudhir Sethi is the company's Chairman. Filings show ongoing compliance with SEBI's Substantial Acquisition of Shares & Takeovers (SAST) Regulations, 2011.

Historical Regulatory Note

While this is a routine promoter purchase, investors note a historical SEBI order from 2013 concerning Beryl Securities Ltd. (potentially related). In that case, promoters, including Sudhir Sethi, faced delays in making a public open offer after crossing shareholding thresholds. Future disclosures and regulatory actions concerning promoter shareholding will be closely monitored.

Peer Landscape

Beryl Drugs operates within the competitive Indian pharmaceutical sector. Key players in this market include large-cap companies such as Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Cipla Ltd., and Torrent Pharmaceuticals Ltd., which are active across various segments from Active Pharmaceutical Ingredients (APIs) to finished formulations.

Investor Focus Ahead

Investors will monitor further stake adjustments by Sudhir Sethi and other promoters. The company's future financial results and market performance will also be key indicators. Ongoing compliance with SEBI regulations, especially regarding substantial acquisitions, remains important.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.